NCT03957681View on ClinicalTrials.gov

A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 23, 2019

Primary Completion Date

October 16, 2020

Study Completion Date

April 11, 2025

Conditions
Moderate to Severe Systemic Sclerosis
Interventions
DRUG

KHK4827

210 mg Q2W, SC

DRUG

Placebo

Q2W, SC

Trial Locations (6)

457-8510

Chukyo Hospital, Nagoya

113-8655

The University of Tokyo Hospital, Tokyo

910-1193

The University of Fukui Hospital, Yoshida-gun

216-8511

St. Marianna University School of Medecine Hospital, Kawasaki

565-0871

Osaka University Hospital, Suita

960-1295

Fukushima Medical University Hospital, Fukushima

All Listed Sponsors
lead

Kyowa Kirin Co., Ltd.

INDUSTRY

NCT03957681 - A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis | Biotech Hunter | Biotech Hunter